The FDA approved IL-1 agonists canakinumab (originally approved for CAPS), anakinra (originally approved for rheumatoid arthritis) and rilonacept (originally approved for CAPS) have shown promise in clinical trials of cardiovascular conditions such as pericarditis and recurrent ischemic events after myocardial infarction [190,191], but thus far none have been approved for these indications. This evidence concerns the gene IL1B and cryopyrin-associated periodic syndrome.